Study on biomarker of Tripterygium wilfordii in treatment of rheumatoid arthritis based on PK/PD.
- Author:
Shi-jia LIU
;
Guo-liang DAI
;
Bing-ting SUN
;
Chang-yin LI
;
Lei WU
;
Ma SHI-TANG
;
Wen-zheng JU
;
Heng-shan TAN
;
Hai-yan FU
- Publication Type:Journal Article
- MeSH:
Animals;
Arthritis, Rheumatoid;
drug therapy;
immunology;
Biomarkers;
Female;
Interleukin-17;
antagonists & inhibitors;
genetics;
Interleukin-6;
genetics;
Phytotherapy;
Rats;
Rats, Sprague-Dawley;
Tripterygium;
Triterpenes;
pharmacokinetics;
pharmacology
- From:
China Journal of Chinese Materia Medica
2015;40(2):334-338
- CountryChina
- Language:Chinese
-
Abstract:
To observe the serum samples and the anti-inflammatory effect of Tripterygium wilfordii in treating RA by using the pharmacokinetic-pharmacodynamic model, make a correlation analysis on concentration-time and effect-time curves, and explore RORγt, IL-17, STAT3, IL-6 mRNA transcriptional levels in rats by PCR. Methotrexate, tripterine and high-dose T. wilfordii could down-regulate RORγt, IL-17, STAT3, IL-6 mRNA transcriptional levels in AA rat lymph nodes. The study on PK-PD model showed correlations between inflammatory factors and blood concentration of T. wilfordii. T. wilfordii and its main active constituent tripterine could show the inflammatory effect and treat RA by inhibiting IL-17 cytokine.
